These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30644585)

  • 41. Tirofiban-associated acute thrombocytopenia.
    Tuhta AG; Yeşildağ O; Köprülü D
    Acta Cardiol; 2006 Oct; 61(5):577-9. PubMed ID: 17117761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications.
    Song JW; Soh S; Shim JK
    Korean J Anesthesiol; 2017 Feb; 70(1):13-21. PubMed ID: 28184261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical outcomes with 6 months dual antiplatelet therapy after implantation of biolimus-A9 drug eluting coronary stents.
    Cockburn J; Pareek N; Poliacikova P; Saraf S; Williams R; Dhillon G; Robinson D; Gerber R; Hatrick R; Blows L; de Belder A; Hildick-Smith D
    Int J Cardiol; 2014 Mar; 172(1):185-9. PubMed ID: 24462139
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contemporary approaches to perioperative management of coronary stents and to preoperative coronary revascularization: a survey of 374 interventional cardiologists.
    Khair T; Garcia B; Banerjee S; Brilakis ES
    Cardiovasc Revasc Med; 2011; 12(2):99-104. PubMed ID: 21421188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.
    Marcano AL; Ferreiro JL
    Curr Atheroscler Rep; 2016 Nov; 18(11):66. PubMed ID: 27714642
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
    Firstenberg MS; Dyke CM; Angiolillo DJ; Ramaiahm C; Price M; Brtko M; Welsby I; Chandna H; Holmes DR; Voeltz M; Tummala P; Hutyra M; Manoukian SV; Prats J; Todd M; Liu T; Chronos N; Dietrich M; Montalescot G; Cannon LA; Topo EJ
    Heart Surg Forum; 2013 Apr; 16(2):E60-9. PubMed ID: 23625478
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cangrelor for the treatment of patients with Arterial Thrombosis.
    Tantry U; Chaudhary R; Kubica J; Bliden K; Gurbel PA
    Expert Opin Pharmacother; 2018 Aug; 19(12):1389-1398. PubMed ID: 30102083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery.
    Savonitto S; Caracciolo M; Cattaneo M; DE Servi S
    J Thromb Haemost; 2011 Nov; 9(11):2133-42. PubMed ID: 21819537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    Bhatt DL; Stone GW; Mahaffey KW; Gibson CM; Steg PG; Hamm CW; Price MJ; Leonardi S; Gallup D; Bramucci E; Radke PW; Widimský P; Tousek F; Tauth J; Spriggs D; McLaurin BT; Angiolillo DJ; Généreux P; Liu T; Prats J; Todd M; Skerjanec S; White HD; Harrington RA;
    N Engl J Med; 2013 Apr; 368(14):1303-13. PubMed ID: 23473369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
    Kereiakes DJ; Kleiman NS; Ambrose J; Cohen M; Rodriguez S; Palabrica T; Herrmann HC; Sutton JM; Weaver WD; McKee DB; Fitzpatrick V; Sax FL
    J Am Coll Cardiol; 1996 Mar; 27(3):536-42. PubMed ID: 8606262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Use of Cangrelor and Heparin for Anticoagulation in a Patient Requiring Pulmonary Thromboendarterectomy Surgery with Suspected Heparin-Induced Thrombocytopenia.
    Seider S; Ross M; Pretorius V; Maus T
    J Cardiothorac Vasc Anesth; 2019 Apr; 33(4):1050-1053. PubMed ID: 29853315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients.
    De Servi S; Morici N; Boschetti E; Rossini R; Martina P; Musumeci G; D'Urbano M; Lazzari L; La Vecchia C; Senni M; Klugmann S; Savonitto S
    Vascul Pharmacol; 2016 May; 80():85-90. PubMed ID: 26657879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of tirofiban in the management of coronary artery disease.
    Winter JP; Juergens CP
    Cardiovasc Hematol Disord Drug Targets; 2008 Jun; 8(2):138-46. PubMed ID: 18537601
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
    Pant S; Neupane P; Ramesh KC; Barakoti M
    Cardiol J; 2011; 18(6):712-7. PubMed ID: 22113766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cangrelor for treatment during percutaneous coronary intervention.
    Oestreich JH; Dobesh PP
    Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.
    Majmundar M; Kansara T; Jain A; Shah P; Mithawala P; Desai R; Shah P; Doshi R
    Am J Cardiol; 2019 Apr; 123(7):1069-1075. PubMed ID: 30654930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cangrelor: a review on pharmacology and clinical trial development.
    Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.